What Score Pharma does

Score Pharma is a private, pre-clinical biotechnology company founded in 2019 and based in Huntsville, Alabama, developing biosuperior monoclonal antibody therapeutics for cancer treatment. The company's proprietary CoreX technology applies reduced core fucosylation to enhance Antibody-Dependent Cellular Cytotoxicity (ADCC), a mechanism that improves the ability of therapeutic antibodies to direct immune cell killing of cancer cells. Score Pharma positions this as a platform capability intended to support multiple biosuperior antibody programs, with the lead program being a biosuperior anti-HER2 trastuzumab antibody targeting HER2-positive breast cancer. The company is led by founder Bruce Edward Jones, who serves as President and CEO, and operates with a small team of 1-10 employees. No ownership structure, institutional investors, or management team beyond the founder is publicly disclosed. The company's commercial model is not yet established: it is pre-revenue, has no disclosed pricing, and has not yet entered clinical trials. The website includes an Investors page, suggesting ongoing capital formation, and a Pipeline page referencing the lead program.

The business model at this stage is research and development of antibody therapeutics intended for future out-licensing, partnership with larger pharmaceutical companies, or independent clinical development and commercialization. There are no marketing or distribution channels in place, consistent with pre-clinical status. A core technology partnership was announced on 2026-03-17 with Asimov, under which Score Pharma will use Asimov's CHO Edge cell line development system as the foundation for proof-of-concept studies on its lead anti-HER2 program. This collaboration enables Score Pharma to pursue its first clinically viable target without building in-house cell line infrastructure. A 2024-06-28 funding event is recorded with Southern Research listed as an investor, though the disclosed dollar amount is $0, indicating a non-dilutive or in-kind support arrangement rather than a priced equity financing. Customer segments are defined at the use-case level as healthcare providers and patients seeking advanced cancer treatments, with the primary pain point addressed being the need for enhanced ADCC activity in antibody treatments for breast cancer.

Name

Score Pharma

Website

https://scorepharma.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Score Pharma is a private pre-clinical biotech developing ADCC-enhanced monoclonal antibody therapeutics using its proprietary CoreX reduced core fucosylation technology, with a lead biosuperior anti-HER2 trastuzumab program for HER2-positive breast cancer patients.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Antibody Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industry

Lead Optimization & Preclinical Candidate Selection (HLAIALAB)

Keywords

• Monoclonal antibody therapeutics
• Biosuperior antibodies
• ADCC enhancement
• Antibody therapeutics platform
• HER2 trastuzumab

Headquarters

HQ city

Huntsville

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Score Pharma is a pre-clinical biotechnology company developing biosuperior monoclonal antibody therapeutics using its proprietary CoreX technology, which applies reduced core fucosylation to enhance Antibody-Dependent Cellular Cytotoxicity (ADCC). Its lead program is a biosuperior anti-HER2 trastuzumab antibody designed for the treatment of HER2-positive breast cancer.

Product overview

Score Pharma operates as an advanced biotech platform focused on developing biosuperior antibody therapeutics for transformative cancer treatment. The company's portfolio centers on its lead program, the Biosuperior Anti-HER2 Trastuzumab (a biosuperior antibody targeting HER2 for breast cancer with enhanced ADCC activity through reduced core fucosylation), supported by its broader Biosuperior Antibody Therapeutics Platform that enables the development of multiple biosuperior antibody programs for cancer treatment.

Differentiator

Problem solved

Functional benefit

Products and services

• Biosuperior Anti-HER2 Trastuzumab A biosuperior anti-HER2 trastuzumab antibody therapeutic for HER2-positive breast cancer, designed to enhance Antibody-Dependent Cellular Cytotoxicity (ADCC) through reduced core fucosylation. Aimed at healthcare providers and patients seeking more effective antibody-based cancer treatments.
• Biosuperior Antibody Therapeutics Platform An advanced biotech platform for developing biosuperior antibody therapeutics targeting cancer, built on proprietary reduced core fucosylation (CoreX) technology that enhances ADCC activity. Serves as the foundation from which the lead trastuzumab program and future antibody candidates are advanced.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• AsimovcoreTechnology or Integration · 17 March 2026Cell line development partnership where Score Pharma leverages Asimov's CHO Edge system as the foundation for proof-of-concept studies on its lead program. Score Pharma is developing a biosuperior anti-HER2 trastuzumab for breast cancer designed to enhance ADCC through reduced core fucosylation. This collaboration enables Score Pharma to pursue its first clinically viable target by accessing Asimov's proprietary cell line development platform.

Recent moves3 records

Expansion highlights4 records

Direct peers

• MacroGenics: Clinical-stage biotech whose lead asset margetuximab is an Fc-engineered anti-HER2 antibody designed to enhance ADCC — the most direct competitive analog to Score Pharma's biosuperior anti-HER2 trastuzumab approach.
• Xencor: Clinical-stage company with a broad Fc-engineering and bispecific antibody platform, including modifications that enhance ADCC and effector function — a directly comparable antibody engineering approach.
• Argenx: Commercial-stage biotech built on an antibody engineering platform (efgartigimod/Vyvgart) that leverages Fc receptor biology; comparable in pursuing engineered antibody therapeutics rather than single-asset development.

Emerging players

• BioAtla: Clinical-stage biotech developing Conditionally Active Biologics, an engineered antibody platform for oncology; comparable as a small, platform-based engineered antibody developer.
• Zymeworks: Develops engineered antibody platforms (Azymetric bispecifics, ZymeLink ADCs) for cancer; comparable as a platform antibody engineering company pursuing oncology applications.
• Compass Therapeutics: Clinical-stage oncology biotech developing engineered antibody therapeutics, including candidates designed to enhance immune effector mechanisms against solid tumors.
• Innate Pharma: Antibody-focused oncology company developing therapeutics that engage innate immune effector cells (e.g., via ADCC), overlapping with Score Pharma's mechanism of action.

Broad incumbents

• Seagen (Pfizer): Pioneer in antibody-drug conjugates for oncology; broader incumbent shaping the competitive landscape for next-generation HER2-targeted and oncology antibody therapeutics.
• AstraZeneca / Daiichi Sankyo: Co-developers of trastuzumab deruxtecan (Enhertu), the leading ADC in HER2-positive breast cancer; represents the primary next-generation competitive threat to any new HER2-targeted antibody.
• Roche (Genentech): Developer of Herceptin (trastuzumab) and the broader HER2 franchise (Perjeta, Kadcyla); defines the current standard of care that any biosuperior HER2 antibody must outperform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Score Pharma